Interestingly, a unique population of CCR2+CCR5+ T cells was found selectively enriched in the CSF of MS patients during relapse but not in patients with other neurologic diseases and proposed as a therapeutic target. The gene discussed is CCR2; the disease is myeloid sarcoma.